(Q54266872)

27 May 2018

title

L-dopa in postencephalitic parkinsonism. (English)

1 reference

27 May 2018

1 reference

1

D B Calne

1 reference

27 May 2018

2

G M Stern

1 reference

27 May 2018

D R Laurence

series ordinal

3

object named as

D R Laurence

1 reference

27 May 2018

J Sharkey

series ordinal

4

object named as

J Sharkey

1 reference

27 May 2018

P Armitage

series ordinal

5

object named as

P Armitage

1 reference

27 May 2018

language of work or name

English

0 references

publication date

1 April 1969

1 reference

27 May 2018

published in

The Lancet

1 reference

27 May 2018

volume

1

1 reference

27 May 2018

issue

7598

1 reference

27 May 2018

page(s)

744-746

1 reference

27 May 2018

Was leistet L-Dopa bei der Behandlung der Parkinson-Akinese?*

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

Reciprocal effects on alpha- and gamma-motoneurones of drugs influencing monoaminergic and cholinergic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

[The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

A method for evaluating disability in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

Modification of Parkinsonism--chronic treatment with L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

Cholinergic-anticholinergic antagonism in parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

Treatment of Parkinson's syndrome with L-dopa. A double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

Dihydroxyphenylalanine in extrapyramidal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

Dopamine metabolism in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

Drug-induced extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

The action of dopamine on neurones of the caudate nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

A double blind study of 1-dopa treatment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2869%2991751-6

7 January 2021

10.1016/S0140-6736(69)91751-6

Identifiers

DOI

1 reference

27 May 2018

PubMed ID

4180215

1 reference

27 May 2018